FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
AbbVie pharmaceutical company announced on Wednesday, Dec. 6, that it will buy Cerevel Therapeutics. This deal is the company's latest attempt to expand its drug pipeline, as its best-selling treatments are currently facing generic competition.
Share Prices Soar with the Buyout Deal
According to CNBC, the share prices of Cerevel Therapeutics shot up to 16% at the close on Wednesday. This is equivalent to almost $43 per share, just a little below the purchase price of over $8 billion.
On the other hand, AbbVie's were said to have slightly gone down by less than 1% in the extended trading. These changes in the share prices show that the acquisition negotiations between the companies have a slight effect on their value.
Agreed Terms of the Deal
AbbVie said that under the agreed terms of the transaction, it will buy all the outstanding shares of Cerevel Therapeutics for the price of $45.00 per share, which will be paid in cash. The deal values the neuroscience drugmaker at about $8.7 billion.
It was mentioned that the companies' respective boards of directors have already greenlighted the deal. This transaction is expected to be completed by mid-2024, subject to regulatory approvals, Cerevel shareholders' approval, and other customary closing conditions.
"Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade," AbbVie's chairman and chief executive officer, Richard A. Gonzalez, said in a press release. "AbbVie will leverage its deep commercial capabilities, international infrastructure, and regulatory and clinical expertise to deliver substantial shareholder value with multibillion-dollar sales potential across Cerevel's portfolio of assets."
Ron Renaud, Crevel Therapeutics' president and chief executive officer, commented, "Cerevel has always been committed to transforming what is possible in neuroscience. With AbbVie's long-standing expertise in developing and commercializing medicines on a global scale, Cerevel's novel therapies will be well positioned to reach more people living with neuroscience diseases."
Photo by: Abbvie Media Resources
